Vice President, Corporate Controller · Sarepta Therapeutics, Inc. (SRPT)

Joseph Bratica

FY2020 is the first fiscal year CompBrief holds for Joseph Bratica as a named executive officer of Sarepta Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$911,887

Salary $326,028Stock awards $237,525

7th of 8 named executive officers at Sarepta Therapeutics by FY2020 total.

8 named officers on file for Sarepta Therapeutics, FY2020

Joseph Bratica’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • SRPT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Sarepta Therapeutics’s whole pay program stands against its peers

  • Sarepta Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SRPT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 20, 2021 (DEF 14A).

Free

Get Joseph Bratica’s full pay file as a PDF — free

More than this page: up to 10 years of Joseph’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Joseph Bratica compensation by year

Sarepta Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Sarepta Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$326,028
Bonus$0
Stock awards$237,525
Option awards$235,848
Non-equity incentive$100,840
Pension and deferred compensation$0
All other$11,645
Total$911,887

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sarepta Therapeutics, Inc. DEF 14A filed April 20, 2021, accession 0001564590-21-019631, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Sarepta Therapeutics, Inc. filed document, accession 0001564590-21-019631. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU2,340$398,947—
RSU2,075$353,767—
RSU2,025$345,242—
Option3,029—$145.48
Option4,188—$71.45
Option4,150—$114.47
Option844—$29.60

Per the Outstanding Equity Awards at Fiscal Year-End table in Sarepta Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Sarepta Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Louise Rodino-KlapacExecutive Vice President, Chief Scientific Officer$7,269,509
David HowtonExecutive Vice President, General Counsel and Corporate Secretary$5,703,078
Ian EstepanExecutive Vice President, Chief Financial Officer$5,177,681
Gilmore O'NeillM.B. Executive Vice President, Chief Scientific Officer$3,790,049
Sandesh MahatmeExecutive Vice President, Chief Financial Officer and Chief Business Officer$3,364,021
Douglas IngramPresident and Chief Executive Officer$1,291,947
Joseph Bratica · this pageVice President, Corporate Controller$911,887
William CiambroneExecutive Vice President, Technical Operations$679,938

The full Sarepta Therapeutics compensation record

free company brief

This page is one person within Sarepta Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Sarepta Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sarepta Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joseph Bratica's compensation dossier · One-time report. No refunds.